Skip to main content

A Risk-Benefit Assessment of Mirtazapine in the Treatment of Depression

Drug Safety volume 17, pages 251–264 (1997)Cite this article

Summary

Mirtazapine is the first of a new class of antidepressants, the noradrenergic and specific serotonergic antidepressants (NaSSA). Its antidepressant effect appears to be related to its dual enhancement of central noradrenergic and serotonin 5-HT1 receptor-mediated serotonergic neurotransmission.

Mirtazapine possesses a number of useful pharmacokinetic characteristics such as good absorption, linear pharmacokinetics over the recommended dosage range (15 to 80 mg/day), and an elimination half-life of 20 to 40 hours, thereby allowing once-daily administration. However, since the drug is extensively metabolised by the hepatic cytochrome P450 (CYP) system and is excreted mainly in the urine, its clearance may be reduced by hepatic or renal impairment. In vitro data suggest that from a clinical point of view it is unlikely that mirtazapine would inhibit the metabolism of coadministered drugs metabolised by CYP1A2, CYP2D6 or CYP3A4. In vivo data from a study in extensive and poor metabolisers of debrisoquine indicate that strong inhibitors of CYP2D6 would have no effect on the concentration of racemic mirtazapine.

In some placebo-controlled studies mirtazapine showed an early onset of antidepressant action, with significant reductions in total Hamilton Depression Rating Scale and Montgomery-Åsberg Depression Rating Scale scores (relative to placebo) noted as early as 1 week after starting treatment. This therapeutic advantage was subsequently maintained during treatment, with mirtazapine proving significantly superior to placebo at treatment end-point in the majority of studies. In comparative trials, the antidepressant efficacy of mirtazapine was comparable with that of tricyclic antidepressants such as amitriptyline, clomipramine and doxepin, and in 2 studies superior to that of trazodone and fluoxetine.

Mirtazapine appears to have a broad spectrum of activity, reflected in its efficacy in a variety of clinical settings. Its additional beneficial effects on the symptoms of anxiety and sleep disturbance associated with depression may reduce the need for concomitant anxiolytic and hypnotic medication seen with some antidepressants.

Mirtazapine has demonstrated superior tolerability to the tricyclic antidepressants and trazodone, primarily on account of its relative absence of anticholinergic, adrenergic and serotonin-related adverse effects, in particular gastrointestinal adverse effects and sexual dysfunction. It appears that increased sedation associated with the drug is related to subtherapeutic dosages, and that it is reported in substantially fewer patients when the drug is used in appropriate dosages (≥15mg as a single evening dose) from the beginning of treatment. Although 2 cases of reversible severe symptomatic neutropenia have been reported in clinical trials, there have been no additional reports of symptomatic neutropenia since the introduction of this drug to various countries in September 1994.

Currently available data and initial clinical experience suggest that with its combination of dual action, simple pharmacokinetics, and clinical efficacy and tolerability, mirtazapine appears to be an important advance in the pharmacotherapy of depression.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. de Boer T, Ruigt GSF. The selective α2-adrenoceptor antagonist mirtazapine (Org 3770) enhances noradrenergic and 5-HT1A-mediated serotonergic neurotransmission. CNS Drugs 1995; 4 Suppl. 1: 29–38

    Article  Google Scholar 

  2. Haddjeri N, Blier P, de Montigny C. Noradrenergic modulation of central serotonergic neurotransmission: acute and longterm actions of mirtazapine. Int Clin Psychopharmacol 1995; 10 Suppl. 4: 11–7

    PubMed  Article  Google Scholar 

  3. de Boer Th. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996; 57 Suppl. 4: 19–26

    PubMed  Google Scholar 

  4. O’Connor WT, Leonard BE. Effect of chronic administration of the 6-aza-analogue of mianserin (Org 3770) and its enantiomers on behaviour and changes in norepinephrine metabolism of olfactory-bulbectomised rats in the ‘open-field apparatus. Neuropharmacology 1985; 25: 267–70

    Article  Google Scholar 

  5. Ruigt GSF, Engelen S, Gerrits A, et al. Computer based prediction of psychotropic drug classes based on a discriminant analysis of drug effects on rat sleep. Neuropsychobiology 1993; 28: 138–53

    PubMed  Article  CAS  Google Scholar 

  6. Svensson T, Bunney BS, Aghajanian GK. Inhibition of both noradrenergic and serotonergic neurons in brain by the α2-adrenergic agonist clonidine. Brain Res 1975; 92: 291–306

    PubMed  Article  CAS  Google Scholar 

  7. Baraban JM, Aghajanian GK. Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoceptor antagonists. Neuropharmacology 1980; 19: 355–63

    PubMed  Article  CAS  Google Scholar 

  8. de Boer T, Maura G, Raiteri M, et al. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology 1988: 27: 399–408

    PubMed  Article  Google Scholar 

  9. de Boer T, Nefkens F, Van Helvoirt A. The α2-antagonist Org 3770 enhances serotonin transmission in vivo. Eur J Pharmacol 1994; 253: R5–6

    PubMed  Article  Google Scholar 

  10. Ruigt GSF, Kemp B, Groenhout CM, et al. Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol 1990; 38: 551–4

    PubMed  Article  CAS  Google Scholar 

  11. Kasper S. Clinical efficacy of mirtazapine: a review of metaanalyses of pooled data. Int Clin Psychopharmacol 1995; 10 Suppl. 4: 25–35

    PubMed  Article  Google Scholar 

  12. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995; 10 Suppl. 4: 37–45

    PubMed  Article  Google Scholar 

  13. Cohen M, Panagides J, Timmer CJ, et al. Pharmacokinetics of mirtazapine from orally administered tablets: influence of a high-fat meal. Eur J Drug Metab Pharmacokinet 1997; 22: 103–10

    PubMed  Article  CAS  Google Scholar 

  14. Timmer CJ, Lohmann AAM, Mink CPA. Pharmacokinetic dose-proportionality study at steady state of mirtazapine from Remeron® tablets. Hum Psychopharmacol 1995; 10 Suppl. 2: S97–106

    Article  CAS  Google Scholar 

  15. Voortman G, Paanakker JE. Bioavailability of mirtazapine from Remeron® tablets after single and multiple oral dosing. Hum Psychopharmacol 1995; 10 Suppl. 2: S83–96

    Article  CAS  Google Scholar 

  16. Delbressine LPC, Vos RME. The clinical relevance of preclinical data. Mirtazapine, a model compound. J Clin Psychopharmacol 1997; 17 Suppl. 1: 29–34

    Article  Google Scholar 

  17. Timmer CJ, Paanakker JE, Vrijmoed-de Vries M. Mirtazapine pharmacokinetics with two dosage regimens and two pharmaceutical formulations. Pharm Res 1997; 14: 98–102

    PubMed  Article  CAS  Google Scholar 

  18. Timmer CJ, Paanakker JE, van Hal HJM. Pharmacokinetics of mirtazapine from orally administered tablets: influence of age, gender and treatment regimen. Hum Psychopharmacol 1996; 11: 497–509

    Article  Google Scholar 

  19. Dahl M-L, Voortman G, Alm C, et al. In vitro and in vivo studies on the disposition of mirtazapine in man. Clin Drug Invest 1997; 13: 37–46

    Article  CAS  Google Scholar 

  20. Mattila M, Mattila MJ, Vrijmoed-de Vries M, et al. Action and interaction of psychotropic drugs on human performance and mood: single doses of Org 3770, amitriptyline and diazepam. Pharmacol Toxicol 1989; 65: 81–8

    PubMed  Article  CAS  Google Scholar 

  21. Sitsen JMA. Lack of pharmacokinetic interaction between mirtazapine and lithium [abstract]. Biol Psychiatry 1997; 42: 45S

    Article  Google Scholar 

  22. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980

    Google Scholar 

  23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. rev. Washington, DC: American Psychiatric Association, 1987

    Google Scholar 

  24. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995; 56: 519–25

    PubMed  CAS  Google Scholar 

  25. Claghorn JL, Lesem MD. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disord 1995; 34: 165–71

    PubMed  Article  CAS  Google Scholar 

  26. Khan MC. A randomised, double-blind, placebo-controlled, 5-weeks study of Org 3770 (mirtazapine) in major depression. Hum Psychopharmacol 1995; 10 Suppl. 2: S119–24

    Article  CAS  Google Scholar 

  27. Smith WT, Glaudin V, Panagides J, et al. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depression. Psychopharmacol Bull 1990; 26: 191–6

    PubMed  CAS  Google Scholar 

  28. Vartiainen H, Leinonen E. Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. Eur Neuropsychopharmacol 1994; 4: 145–50

    PubMed  Article  CAS  Google Scholar 

  29. Jacobson AF, Dominguez RA, Goldstein B et al. Comparison of Org 3770 and amitriptyline in depressed outpatients [abstract]. J Clin Pharmacol 1990; 30: 851

    Google Scholar 

  30. Halikas JA. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol 1995; 10 Suppl. 2: S125–33

    Article  CAS  Google Scholar 

  31. Mullin J, Lodge A, Bennie E, et al. A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with depression. J Psychopharmacol 1996; 10: 235–40

    PubMed  Article  CAS  Google Scholar 

  32. Zivkov M, de Jongh GD. Org 3770 versus amitriptyline: a 6-week randomized double-blind trial in hospitalized depressed patients. Hum Psychopharmacol 1995; 10: 173–80

    Article  Google Scholar 

  33. Høyberg OJ, Maragakis B, Mullin J, et al. Adouble-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand 1996; 93: 184–90

    PubMed  Article  Google Scholar 

  34. Richou H, Ruimy P, Charbaut J, et al. A multicentre, doubleblind, clomipramine-controlled efficacy and safety study of Org 3770. Hum Psychopharmacol 1995; 10: 263–71

    Article  CAS  Google Scholar 

  35. Mattila M, Jääskeläinen J, Järvi R, et al. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol 1995; 5: 441–6

    Google Scholar 

  36. van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with depression. Int Clin Psychopharmacol 1995; 10: 3–9

    PubMed  Article  Google Scholar 

  37. Wheatley D, Kramer CME. A randomised, double-blind comparison of mirtazapine and fluoxetine in patients with major depression [abstract]. American Psychiatric Association Annual Meeting; 1997 May 17–22: San Diego, New Research Program and Abstracts: 124

  38. Kasper S. Clinical efficacy of mirtazapine: a pooled-data analysis of four US studies [abstract]. 35th Annual Meeting of the American College of Neuropsychopharmacology (ACNP); 1996 Dec 8–13: San Juan, Puerto Rico: 107

  39. Zivkov M, Roes KCB, Pols AG. Efficacy of Org 3770 (mirtazapine) vs amitriptyline in patients with major depressive disorder: a meta-analysis. Hum Psychopharmacol 1995; 10 Suppl. 2: S135–45

    Article  CAS  Google Scholar 

  40. Bruijn JA, Moleman P, Mulder PGH, et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology 1996; 127: 231–7

    PubMed  Article  CAS  Google Scholar 

  41. Kasper S, Zivkov M, Roes KCB, et al. Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline. Eur Neuropsychopharmacol 1997; 7: 115–24

    PubMed  Article  CAS  Google Scholar 

  42. Kasper S. Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. J Clin Psychopharmacol 1997; 17 Suppl. 1: 19–29

    Article  Google Scholar 

  43. Akiskal H. Mood disorders: clinical features. In: Kaplan HI, Sadock BJ, editors. Comprehensive textbook of psychiatry VI. Baltimore (MD): Williams and Wilkins, 1995: 1123–52

    Google Scholar 

  44. Kasper S. Mirtazapine: a novel antidepressant combining clinical efficacy with improved tolerability. Primary Care Psychiatry 1997; 3: 7–16

    Google Scholar 

  45. Sitsen JMA, Moors J. Mirtazapine, a novel antidepressant, in the treatment of anxiety symptoms: results from a placebocontrolled trial. Drug Invest 1994; 8: 339–44

    Google Scholar 

  46. Bremner JD, Smith WT. Org 3770 vs amitriptyline in the continuation treatment of depression: a placebo controlled trial. Eur J Psychiatry 1996; 10: 5–15

    Google Scholar 

  47. Bech P, Allerup P, Reisby N, et al. Assessment of symptom change from improvement curves on the Hamilton depression scale in trials with antidepressants. Psychopharmacology 1984; 84: 276–81

    PubMed  Article  CAS  Google Scholar 

  48. Burrows GD, Kremer CME. Mirtazapine: clinical advantages in the treatment of depression. J Clin Psychopharmacol 1997; 17 Suppl. 1: 34–9

    Article  Google Scholar 

  49. Stahl SM, Kremer CME, Pinder RM. Tolerability of mirtazapine used in high or low initial dose [abstract]. American Psychaitric Association Annual Meeting; 1997 May 17–22; San Diego, New Research Program and Abstracts: 133

  50. Richelson E. The pharmacologic rationale behind antidepressant efficacy in severe depression. J Clin Psychiatry 1996; 57: 559–60

    Google Scholar 

  51. Klint T, Helsdingen JT, Kremer CME, et al. Lack of typical SSRI-related adverse events and sexual dysfunction with mirtazapine is related to specific blockade of 5-HT2 and 5-HT3 receptors [abstract]. Eur Neuropsychopharmacol 1996; 6 Suppl. 4: 62

    Google Scholar 

  52. Rudorfer MV, Manji HK, Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf 1994; 10: 18–46

    PubMed  Article  CAS  Google Scholar 

  53. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ 1995; 310: 221–4

    PubMed  Article  CAS  Google Scholar 

  54. de Jonghe F, Swinkels JA. The safety of antidepressants. Drugs 1992; 43 Suppl. 2: 40–7

    PubMed  Article  Google Scholar 

  55. Boyer WF, Blumhardt CL. The safety profile of paroxetine. J Clin Psychiatry 1992; 53: 61–6

    PubMed  Google Scholar 

  56. Doogan DP. Toleration and safety of sertraline: experience worldwide. Int Clin Psychopharmacol 1991; 6 Suppl. 2: 47–56

    PubMed  Article  Google Scholar 

  57. Wernicke JF. The side effect profile and safety of fluoxetine. J Clin Psychiatry 1985; 46: 59–67

    PubMed  CAS  Google Scholar 

  58. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705–13

    PubMed  CAS  Google Scholar 

  59. Mann JJ, Kapur S. The emergence of suicidal ideation and behaviour during antidepressant pharmacotherapy. Arch Gen Psychiatry 1991; 48: 1027–33

    PubMed  Article  CAS  Google Scholar 

  60. Kasper S, Schindler S, Neumeister A. Risk of suicide in depression and its implications for psychopharmacological treatment. Int Clin Psychopharmacol 1996; 11: 71–9

    PubMed  CAS  Google Scholar 

  61. Clifford Lane H, Fauci AS. Sjögrens syndrome. In: Wilson JD, Braunwald E, Isselbacher KJ, et al., editors. Harrisons principles of internal medicine. 12th ed. New York: McGraw-Hill Inc. Health Professions Division, 1991: 1449–50

    Google Scholar 

  62. Heimpel H. Drug-induced agranulocytosis. Med Toxicol 1988; 3: 449–62

    CAS  Google Scholar 

  63. Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993; 54: 289–99

    PubMed  CAS  Google Scholar 

  64. Hoes MJAJM, Zijpveld JHB. First report of mirtazapine overdose [letter]. Int Clin Psychopharmacol 1996; 11: 147

    PubMed  CAS  Google Scholar 

  65. Zivkov M, Kremer CME, Hoes MJAJM, et al. Safety of mirtazapine in overdose [abstract]. Eur Neuropsychopharmacol 1996; 6 Suppl. 4: 62

    Google Scholar 

Download references

Author information

Affiliations

  1. Department of General Psychiatry, University of Vienna, Währinger Gürtel 18-20, A-1090, Vienna, Austria

    Siegfried Kasper, Nicole Praschak-Rieder, Johannes Tauscher & Rainer Wolf

Authors
  1. Siegfried Kasper
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicole Praschak-Rieder
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Johannes Tauscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rainer Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kasper, S., Praschak-Rieder, N., Tauscher, J. et al. A Risk-Benefit Assessment of Mirtazapine in the Treatment of Depression. Drug-Safety 17, 251–264 (1997). https://doi.org/10.2165/00002018-199717040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199717040-00005

Keywords

  • Adis International Limited
  • Amitriptyline
  • Sexual Dysfunction
  • Mirtazapine
  • Clomipramine